CALCIUM AND BLOOD PRESSURE

The Lancet

Volumn 319, Issue 8276, 1982, Pages 813-815

  Kesteloot, Hugo ^a   Geboers, Jozef ^a  

^a QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM;

BELGIUM; BLOOD PRESSURE; CALCIUM URINE LEVEL; CARDIOVASCULAR SYSTEM; DIAGNOSIS; EPIDEMIOLOGY; ETIOLOGY; POTASSIUM URINE LEVEL; SHORT SURVEY; SODIUM URINE LEVEL;

ADULT; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CALCIUM; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; MIDDLE AGE; POTASSIUM; SODIUM;

EID: 0020054743     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(82)91870-0     Document Type: Article

References (21)

1. Humoral factors in the sodium-potassium pump in volume expanded hypertension
2. Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis
3. Ueber den Niederschlag welche Pikrinsaure in normalem Harn erzeugt und ueber eine neue Reaktion des Kreatinins
4. Indicator for the titration of calcium in presence of magnesium using disodium dihydrogen ethylenediamine tetraacetate
5. New complexon for titration of calcium in the presence of magnesium
6. Relationship between blood pressure and sodium and potassium intake in a Belgian male population group
7. The relationship between blood pressure and biochemical risk factors in a general population
8. Factors influencing the urinary excretion of calcium
9. Studies in calcium metabolism. I. The calciuretic effect of dietary protein
10. Calcium and fat absorption in the neonatal period
11. The effect of dietary calcium supplementation on serum calcium, phosphorus and alkaline phosphate concentrations in a rural black population
12. Electrolytes, environment and blood pressure
13. Electrolytes and hypertension
14. Natriuretic hormone
15. Normalisation of blood pressure in spontaneously hypertensive rats by longterm oral treatment with verapamil and nifedipine
16. Der Einfluss von BAY a 1040 auf die Nierenfunktion des Hypertonikers
17. Clinical experience with a new coronary-active substance (BAY a 1040)
18. 2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade